Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | ACHE | P22303 | 6/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.42 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23115366 | 0.96 | CA12 (0.46) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL25239638 | 0.94 | CA12 (0.44) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL25201565 | 0.94 | CA12 (0.44) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL25204665 | 0.94 | CA12 (0.44) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL23115411 | 0.91 | TDP1 (0.42) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL23115414 | 0.91 | MAOA (0.45) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL31284031 | 0.90 | CA12 (0.59) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL25181487 | 0.90 | CA12 (0.59) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL31357657 | 0.89 | TDP1 (0.51) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL31325275 | 0.89 | TDP1 (0.51) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051263-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SAIL BIOMEDICINES, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4436549-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | Sail Biomedicines, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023091787-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SENDA BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051263-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | NPC1L1, ABCB4, LIPA | CA12 1271/4885CA1 2457/4885CA2 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.